Article
Oncology
Ze Zhang, Tianyu Jiao, Junfeng Li, Bingyang Hu, Wenwen Zhang, Zhijun Wang, Tao Wan, Yafei Wang, Shichun Lu
Summary: This study aimed to explore the potential efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent HCC. The results showed that the combination therapy of TKIs and PD-1 inhibitors can significantly prolong the survival of patients.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Review
Gastroenterology & Hepatology
Lorenza Rimassa, Richard S. Finn, Bruno Sangro
Summary: Single-agent immune checkpoint inhibitors (ICIs) have limited efficacy in advanced hepatocellular carcinoma (HCC) patients, and approximately 30% of patients show intrinsic resistance to ICIs. Therefore, researchers are exploring combination therapies, such as anti-angiogenic agents and other ICIs. Some trials have shown promising results and potential for clinical application. However, there are still many unanswered questions that require further research.
JOURNAL OF HEPATOLOGY
(2023)
Review
Immunology
Rohini Sharma, Leila Motedayen Aval
Summary: The treatment landscape for hepatocellular cancer (HCC) has shifted with the introduction of immune checkpoint inhibitors (ICIs) showing potential for improved survival in first-line treatment. However, response rates to ICIs are limited and patients will still progress. The optimal second-line therapies following exposure to ICIs remain unclear.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Samantha Armstrong, Tina Roy, Bhavana Singh, Monika Kulasekaran, Fatima Shaukat, Xue Geng, Hongkun Wang, Petra Prins, Reena C. Jha, Marion L. Hartley, Aiwu Ruth He
Summary: This study found that disease control predicts prolonged overall survival (mOS) and progression-free survival (mPFS) in patients with advanced HCC. Furthermore, TKI therapy administered after immunotherapy predicts prolonged mOS in these patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Lisha Mou, Xiaohe Tian, Bo Zhou, Yongqiang Zhan, Jiao Chen, Ying Lu, Jing Deng, Ying Deng, Zijing Wu, Qi Li, Yi'an Song, Hongyuan Zhang, Jinjun Chen, Kuifeng Tian, Yong Ni, Zuhui Pu
Summary: Targeted therapies like TKIs are crucial for advanced HCC treatment, with combination therapies involving immune checkpoint inhibitors showing promise. Nanoparticle-based TKI delivery techniques are also expected to enhance treatment efficacy, making it more efficient.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Tao Sun, Yanqiao Ren, Bo Sun, Lei Chen, Licheng Zhu, Lijie Zhang, Chuansheng Zheng
Summary: In patients with advanced hepatocellular carcinoma, transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs: sorafenib, lenvatinib, and apatinib) plus camrelizumab (TACE-TKIs-C) improves overall survival and progression-free survival compared to TACE combined with TKIs (TACE-TKIs) with manageable safety profile.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2023)
Review
Oncology
Bernardo Stefanini, Luca Ielasi, Rusi Chen, Chiara Abbati, Matteo Tonnini, Francesco Tovoli, Alessandro Granito
Summary: The treatment landscape of hepatocellular carcinoma (HCC) has significantly changed over the last 5 years, with multiple options in the frontline, second line, and beyond. Tyrosine kinase inhibitors (TKIs) were the first approved systemic treatments for advanced stage HCC, but the use of immune checkpoint inhibitors (ICI) in combination with TKIs has expanded the systemic treatment options for HCC and shown higher efficacy.
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Article
Oncology
Manon Falette-Puisieux, Jean-Charles Nault, Mohamed Bouattour, Marie Lequoy, Giuliana Amaddeo, Thomas Decaens, Frederic Di Fiore, Sylvain Manfredi, Philippe Merle, Aurore Baron, Christophe Locher, Anna Pellat, Romain Coriat
Summary: This retrospective study evaluated the efficacy and safety of second-line tyrosine kinase inhibitors (TKIs) in patients with advanced hepatocellular carcinoma (HCC). The results showed that the efficacy of TKIs as a second-line treatment was not affected by prior atezolizumab-bevacizumab therapy. However, regorafenib was associated with better overall survival (OS) and overall global survival (OGS) rates compared to other TKIs. These findings should be confirmed in prospective comparative studies.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Immunology
Hui Zeng, Qi Xu, Jinyu Wang, Xiaoqing Xu, Jun Luo, Lei Zhang, Cong Luo, Jieer Ying, Jingjing Li
Summary: This study found that the efficacy and safety of immune checkpoint inhibition (ICI) plus bevacizumab (BEV) and ICI plus receptor tyrosine kinase inhibitor (TKI) were similar as first-line treatments for unresectable hepatocellular carcinoma (uHCC).
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Jeffrey Sum-Lung Wong, Yawen Dong, Vikki Tang, Thomas Leung, Cynthia S. Y. Yeung, Anna Tai, Ada Law, Tracy Shum, Gerry Gin-Wai Kwok, Bryan Cho-Wing Li, Roland Leung, Joanne Chiu, Ka-Wing Ma, Wong-Hoi She, Josephine Tsang, Tan-To Cheung, Thomas Yau
Summary: Cabozantinib showed good anti-tumor activity, survival benefits, and acceptable tolerability in real-life advanced HCC patients. The study evaluated the real-world use, efficacy, and safety of cabozantinib in aHCC patients.
Review
Oncology
Blanca Cucarull, Anna Tutusaus, Patricia Rider, Tania Hernaez-Alsina, Carlos Cuno, Pablo Garcia de Frutos, Anna Colell, Montserrat Mari, Albert Morales
Summary: Hepatocellular carcinoma (HCC) is the most common form of liver cancer with poor prognosis and increasing incidence. Recent advances in systemic treatment options, including tyrosine kinase inhibitors, antiangiogenic antibodies, and immune checkpoint inhibitors, have provided hope for HCC patients. Understanding the specific molecular mechanisms that influence tumor growth and immune control in HCC is crucial for physician decision-making and developing effective treatments.
Article
Oncology
Laihui Luo, Yongqiang Xiao, Guoqing Zhu, Aihong Huang, Shengjiang Song, Tao Wang, Xian Ge, Jin Xie, Wei Deng, Zhigao Hu, Wu Wen, Haoran Mei, Renhua Wan, Renfeng Shan
Summary: This study investigated the efficacy and safety of combining hepatic arterial infusion chemotherapy (HAIC), programmed cell death protein-1 (PD-1) inhibitors, and tyrosine kinase inhibitors (TKIs) for patients with unresectable hepatocellular carcinoma (u-HCC). The results showed that the triple combination therapy exhibited satisfactory efficacy with tolerable toxicity in treating u-HCC patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Hui Hua, Jiajia Zeng, Haixin Xing, Yuxin He, Linyu Han, Nasha Zhang, Ming Yang
Summary: This study systematically evaluated the role of genetic variants in A-to-I editing genes on the prognosis of NSCLC patients receiving EGFR-TKIs therapy. The researchers identified several SNPs in the ADAR gene that were significantly associated with patient prognosis and found that silencing ADAR enhanced the sensitivity of NSCLC cells to gefitinib. These findings highlight the importance of A-to-I RNA editing in drug resistance and suggest ADAR as a potential therapeutic target for unresectable NSCLC.
Review
Biochemistry & Molecular Biology
Monica A. Kamal, Yasmine M. Mandour, Mostafa K. Abd El-Aziz, Ulrike Stein, Hend M. El Tayebi
Summary: Liver cancer is a common and limitedly treated type of cancer. Recently, new target proteins and pathways have been discovered, leading to the design of new drugs. This review provides an overview of these targets and compounds.
Article
Biochemistry & Molecular Biology
Summer Sofer, Kevin Lamkiewicz, Shir Armoza Eilat, Shirly Partouche, Manja Marz, Neta Moskovits, Salomon M. Stemmer, Amir Shlomai, Ella H. Sklan
Summary: This study identified Hexokinase 1 (HK1) as a top candidate gene associated with tyrosine-kinase inhibitor (TKI) resistance in hepatoma cells. HK1 expression was upregulated in regorafenib-resistant cells, and an HK inhibitor resensitized resistant cells to TKI treatment. These findings suggest that HK1 may serve as a biomarker for treatment success in hepatocellular carcinoma.